 |
|
Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women
Erik Ingelsson, MD, PhD;
Ernst J. Schaefer, MD;
John H. Contois, PhD;
Judith R. McNamara, MT;
Lisa Sullivan, PhD;
Michelle J. Keyes, MA;
Michael J. Pencina, PhD;
Christopher Schoonmaker, MA;
Peter W. F. Wilson, MD;
Ralph B. D’Agostino, PhD;
Ramachandran S. Vasan, MD
JAMA. 2007;298:776-785.
Context Evidence is conflicting regarding the performance of apolipoproteins vs traditional lipids for predicting coronary heart disease (CHD) risk.
Objectives To compare performance of different lipid measures for CHD prediction using discrimination and calibration characteristics and reclassification of risk categories; to assess incremental utility of apolipoproteins over traditional lipids for CHD prediction.
Design, Setting, and Participants Population-based, prospective cohort from, Framingham, Massachusetts. We evaluated serum total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non–HDL-C, apolipoprotein (apo) A-I and apo B, and 3 lipid ratios (total cholesterol:HDL-C, LDL-C:HDL-C, and apo B:apo A-I) in 3322 middle-aged white participants who attended the fourth offspring examination cycle (1987-1991) and were without cardiovascular disease. Fifty-three percent of the participants were women.
Main Outcome Measure Incidence of first CHD event (recognized or unrecognized myocardial infarction, angina pectoris, coronary insufficiency, or coronary heart disease death).
Results After a median follow-up of 15.0 years, 291 participants, 198 of whom were men, developed CHD. In multivariate models adjusting for nonlipid risk factors, the apo B:apo A-I ratio predicted CHD (hazard ratio [HR] per SD increment, 1.39; 95% confidence interval [CI], 1.23-1.58 in men and HR, 1.40; 95% CI, 1.16-1.67 in women), but risk ratios were similar for total cholesterol:HDL-C (HR, 1.39; 95% CI, 1.22-1.58 in men and HR, 1.39; 95% CI, 1.17-1.66 in women) and for LDL-C:HDL-C (HR, 1.35; 95% CI, 1.18-1.54 in men and HR, 1.36; 95% CI 1.14-1.63 in women). In both sexes, models using the apo B:apo A-I ratio demonstrated performance characteristics comparable with but not better than that for other lipid ratios. The apo B:apo A-I ratio did not predict CHD risk in a model containing all components of the Framingham risk score including total cholesterol:HDL-C (P = .12 in men; P = .58 in women).
Conclusions In this large, population-based cohort, the overall performance of apo B:apo A-I ratio for prediction of CHD was comparable with that of traditional lipid ratios but did not offer incremental utility over total cholesterol:HDL-C. These data do not support measurement of apo B or apo A-I in clinical practice when total cholesterol and HDL-C measurements are available.
Author Affiliations: The Framingham Study, Boston University School of Medicine, Framingham (Drs Ingelsson, Pencina, D’Agostino, and Vasan and Ms Keyes); Lipid Metabolism Laboratory, Jean Mayer US Department of Agriculture, Human Nutrition Research Center on Aging at Tufts University, Boston (Drs Schaefer and Contois and Ms McNamara); Departments of Biostatistics, School of Public Health (Dr Sullivan), Mathematics and Statistics (Ms Keyes, Drs Pencina and D’Agostino, and Mr Schoonmaker), and Preventive Medicine, Cardiology Section, School of Medicine (Dr Vasan), Boston University, Boston, Massachusetts; and Cardiology Division, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Wilson).
RELATED LETTERS
Utility of Different Lipid Measures to Predict Coronary Heart Disease
Justo Sierra-Johnson, Abel Romero-Corral, and Francisco Lopez-Jimenez
JAMA. 2008;299(1):35.
EXTRACT
| FULL TEXT
Utility of Different Lipid Measures to Predict Coronary Heart Disease
Joshua Remick, James A. Underberg, and Nirav R. Shah
JAMA. 2008;299(1):35-36.
EXTRACT
| FULL TEXT
Utility of Different Lipid Measures to Predict Coronary Heart Disease—Reply
Erik Ingelsson, Michael J. Pencina, Ralph B. D’Agostino, and Ramachandran S. Vasan
JAMA. 2008;299(1):36.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
Kastelein et al.
Circulation 2008;117:3002-3009.
ABSTRACT
| FULL TEXT
Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis
Owens et al.
Arch Intern Med 2008;168:1200-1207.
ABSTRACT
| FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT
Utility of Different Lipid Measures to Predict Coronary Heart Disease
Sierra-Johnson et al.
JAMA 2008;299:35-35.
FULL TEXT
Utility of Different Lipid Measures to Predict Coronary Heart Disease
Remick et al.
JAMA 2008;299:35-36.
FULL TEXT
Fasting versus Nonfasting Triglycerides: Implications for Laboratory Measurements
Warnick and Nakajima
Clin. Chem. 2008;54:14-16.
FULL TEXT
What's the Utility of the Apo B:Apo A-1 Ratio?
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT
|
